Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana).
NCT03964051 · Carsten Bindslev-Jensen · PHASE4 · terminated · last registry update 2023-12-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Finished” | – | Registry record, Carsten Bindslev-Jensen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGHE within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-08Results posted on the registry: Novartis Pharmaceuticals, ligelizumab + Placebo (NCT04984876)
- 2024-09-19Also stopped (terminated): Stanford University, omalizumab + dupliumab (NCT04943744)
- 2024-07-03Also stopped (withdrawn): University of California, Davis, Rituximab combined with Omalizumab (NCT04128176)
- 2024-06-20Also stopped (terminated): Novartis Pharmaceuticals, Ligelizumab (NCT04210843)
- 2024-06-18Also stopped (terminated): Novartis Pharmaceuticals, Ligelizumab (NCT05024058)
- 2024-06-18Also stopped (terminated): Novartis Pharmaceuticals, Ligelizumab + Placebo (NCT04513548)
- 2024-06-04Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Omalizumab + Placebo for Omalizumab (NCT03881696)
- 2024-05-01Results posted on the registry: Amgen, Tezepelumab Dose 1 + Tezepelumab Dose 2 (NCT04833855)
- 2024-04-15Phase 3 first posted: Taizhou Mabtech Pharmaceutical Co.,Ltd, CMAB007 + Xolair (NCT06365879)
- 2024-03-25Results posted on the registry: Novartis Pharmaceuticals, Ligelizumab + Omalizumab (NCT03580356)
- 2024-03-08Results posted on the registry: Novartis Pharmaceuticals, Ligelizumab (NCT03907878)
- 2023-09-18Phase 3 first posted: Novartis Pharmaceuticals, Remibrutinib + Placebo to remibrutinib (NCT06042478)
- 2023-09-15Results posted on the registry: Novartis Pharmaceuticals, Ligelizumab (NCT05024058)
- 2023-07-13Results posted on the registry: Novartis Pharmaceuticals, Ligelizumab (NCT04210843)
- 2023-05-11Results posted on the registry: Celltrion, CT-P39 + EU-approved Xolair (NCT04018313)
- 2023-04-14Phase 3 first posted: Cinnagen, Omalizumab (CinnaGen) + Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) (NCT05813470)
- 2023-03-17Phase 3 first posted: Kashiv BioSciences, LLC, Omalizumab Injection + Xolair Prefilled Syringe (NCT05774639)
- 2023-01-10Phase 3 first posted: Novartis Pharmaceuticals, Ligelizumab 120 mg + Ligelizumab 240 mg (NCT05678959)
- 2022-12-30Results posted on the registry: Novartis Pharmaceuticals, Ligelizumab + Omalizumab (NCT03580369)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision